Disc Medicine reports FY2023 net loss $76.4M, cash $360.4M; AURORA topline data expected March/April 2024

Disc Medicine, Inc.

Cash and cash equivalents $360.4M at Dec 31, 2023, providing runway well into 2026.
Net loss of $76.4M for FY2023 vs $46.8M in 2022, driven by higher R&D costs ($69.3M vs $33.4M).
Topline results from AURORA phase 2 study of bitopertin in EPP expected March/April 2024.
Updated phase 1b/2 data for DISC-0974 in anemia of myelofibrosis expected 1H 2024.
Appointed Jean Franchi as CFO, Pamela Stephenson as CCO, promoted Jonathan Yu to COO.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Disc Medicine, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income Net loss was $76.4 million.

Period: the fourth quarter and full year ended December 31, 2023
Net income: Net loss was $76.4 million
Result: reported results

Exact text from the filing

Disc Medicine, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Disc Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-073324

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.